All Entries in the "Research Reports" Category

Dutton Associates continues coverage of Pluristem Therapeutics (Nasdaq: PTSI) reiterating its Speculative Buy rating and a 12-month $6.50 price target.

Dutton Associates continues coverage of Pluristem Therapeutics (Nasdaq: PTSI) reiterating its Speculative Buy rating and a 12-month $6.50 price target. The 10-page report by Dutton senior analyst Denise T. Resnik, MS is available at www.duttonassociates.com, and at First Call, Bloomberg, Capital IQ, FactSet, Reuters, Zacks, Knobias, and other leading financial portals.
View the full Dutton Associates [...]

Share and Enjoy:

August 05, 2008 | admin | Comments 0

TheSUBWAY.com - Presenting an Interesting Find to Our Subscribers, KBLB Recent Report from Emerging Growth

TheSUBWAY.com wants to present an interesting find to our subscribers, KBLB, take a look at this stock, and take a look at this recent research report from Emerging Growth…
The report is available for free download at: http://www.kraiglabs.com/pdf/KBLBReport.pdf

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB), Emerging Growth Research, LLP issued a report late last month on Kraig Biocraft [...]

Share and Enjoy:

August 05, 2008 | admin | Comments 0

- Subscribe
- Archives
- Tags
- Popular
Get Our Daily Email Newsletter!

Name:

Email:

TheSUBWAY Newsletter contains Stock Picks, News, and Information. Receive your daily Stock Market updates today. Your name and email are kept private and never shared or sold.

This feature has not been activated yet.
Categories
Archives
Blogroll

This Blog is owned / managed by CRG Partners, Inc. (CRGP). Posts made by CRGP are based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this Forum have not approved the statements made in this Forum. This Forum contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.TheSUBWAY.com or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this Forum. CRGP may sell its shares for less than the target price given in its investment opinions. In addition to any compensation mentioned on www.TheSUBWAY.com, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site operates under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's Licensors, affiliates, officers, directors and employees own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

RSS Feeds


	Other RSS Reader